🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Triple Negative Locally Advanced Non-resectable Breast Cancer

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer NCT06434064Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites📍 Los Angeles📍 Los Angeles📍 Boston Marengo Therapeutics, Inc. · Tests: STAR0602, Sacituzumab Govitecan (SG) Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer NCT05422794Phase 16 sites📍 Boston📍 Boston📍 Mineola National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance I… Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer NCT06324240Phase 14 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Ipilimumab, Pembrolizumab, Vaccine Therapy A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites📍 Boston📍 St Louis National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care NCT07533123Phase 31 site📍 Guangzhou Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Tests: JSKN016 Injection, Eribulin Mcsilate Injection, Vinorelbine Tartrate Injection, Capecitabine Tablets, Gemcitabine Hydro… AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site📍 Beijing Akeso · Tests: AK112, Nab-paclitaxel, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy